Sarah Ballou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5624200/publications.pdf

Version: 2024-02-01

489802 466096 1,153 49 18 32 citations h-index g-index papers 50 50 50 1328 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Doctors Speak: A Qualitative Study of Physicians' Prescribing of Antidepressants in Functional Bowel Disorders. Culture, Medicine and Psychiatry, 2023, 47, 669-683.	0.7	2
2	Clinical and Psychological Factors Predict Outcome in Patients With Functional Dyspepsia: A Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, 1251-1258.e1.	2.4	10
3	Symptom severity and clinical characteristics of patients with bloating. Neurogastroenterology and Motility, 2022, 34, e14229.	1.6	8
4	Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders. Neurogastroenterology and Motility, 2022, 34, e14253.	1.6	2
5	Diminished androgen levels are linked to irritable bowel syndrome and cause bowel dysfunction in mice. Journal of Clinical Investigation, 2022, 132, .	3.9	10
6	Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials. JAMA Network Open, 2022, 5, e2143955.	2.8	99
7	Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study. BMC Psychology, 2022, 10, 20.	0.9	15
8	Association of Thought Impact Scale Scores with Hypnosis Treatment Responses and Hypnotherapy-Seeking: A Confirmation Study. International Journal of Clinical and Experimental Hypnosis, 2022, 70, 28-48.	1.1	1
9	Are They Side Effects? Extraintestinal Symptoms Reported During Clinical Trials of Irritable Bowel Syndrome May Be More Severe at Baseline. Clinical Gastroenterology and Hepatology, 2022, 20, 2888-2894.e1.	2.4	2
10	Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. Scandinavian Journal of Gastroenterology, 2022, 57, 406-414.	0.6	2
11	Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome. Psychosomatic Medicine, 2022, 84, 738-746.	1.3	5
12	Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial. Pain, 2021, 162, 2428-2435.	2.0	52
13	Women's health factors and altered bowel habits: results of a National Health And Nutrition Examination Survey. GastroHep, 2021, 3, 141-150.	0.3	O
14	Abdominal Pain and Depression, Not Bowel Habits, Predict Health Care Utilization in Patients With Functional Bowel Disorders. American Journal of Gastroenterology, 2021, 116, 1720-1726.	0.2	14
15	Improving Medication Tolerance. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	1.1	4
16	Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. American Journal of Gastroenterology, 2021, 116, 2279-2285.	0.2	19
17	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. Gastroenterology, 2020, 158, 786-788.e1.	0.6	33
18	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 2840-2842.	2.4	5

#	Article	IF	Citations
19	Similarities in Clinical and Psychosocial Characteristics of Functional Diarrhea and Irritable Bowel Syndrome With Diarrhea. Clinical Gastroenterology and Hepatology, 2020, 18, 399-405.e1.	2.4	19
20	Validation of the Pandemic Emotional Impact Scale. Brain, Behavior, & Immunity - Health, 2020, 9, 100161.	1.3	16
21	Hypnosis and Cognitive Behavioral Therapies for the Management of Gastrointestinal Disorders. Current Gastroenterology Reports, 2020, 22, 31.	1.1	20
22	Brief Behavioral Therapy for Insomnia in Patients with Irritable Bowel Syndrome: A Pilot Study. Digestive Diseases and Sciences, 2020, 65, 3260-3270.	1.1	9
23	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 1899.	2.4	0
24	Symptom Severity, Mood, and Healthcare Use Are Associated With Satisfaction in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 2945-2951.e1.	2.4	6
25	Editorial: symptom improvement does not equal satisfaction with treatment for constipation. Alimentary Pharmacology and Therapeutics, 2020, 51, 909-910.	1.9	4
26	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. Clinical Gastroenterology and Hepatology, 2019, 17, 2471-2478.e3.	2.4	65
27	Obesity is associated with significantly increased risk for diarrhoea after controlling for demographic, dietary and medical factors: a crossâ€sectional analysis of the 2009â€2010 National Health and Nutrition Examination Survey. Alimentary Pharmacology and Therapeutics, 2019, 50, 1019-1024.	1.9	21
28	Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia. Journal of Neurogastroenterology and Motility, 2019, 25, 129-136.	0.8	7
29	Chronic Diarrhea and Constipation Are More Common in Depressed Individuals. Clinical Gastroenterology and Hepatology, 2019, 17, 2696-2703.	2.4	56
30	Emergency department visits for depression in the United States from 2006 to 2014. General Hospital Psychiatry, 2019, 59, 14-19.	1.2	22
31	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1216.	2.4	0
32	Fecal urgency is common in constipated patients and is associated with anxiety. Neurogastroenterology and Motility, 2019, 31, e13545.	1.6	11
33	Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2019, 10, e00110.	1.3	15
34	Placebo Response in Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2019, 114, 1838-1846.	0.2	18
35	Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States. American Journal of Gastroenterology, 2019, 114, 135-142.	0.2	49
36	Significant Morbidity and Mortality Associated with Fecal Impaction in Patients Who Present to the Emergency Department. Digestive Diseases and Sciences, 2019, 64, 1320-1327.	1.1	15

3

#	Article	IF	CITATIONS
37	Demographic and Dietary Associations of Chronic Diarrhea in a Representative Sample of Adults in the United States. American Journal of Gastroenterology, 2018, 113, 593-600.	0.2	39
38	Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. Alimentary Pharmacology and Therapeutics, 2018, 47, 913-921.	1.9	34
39	Risk Factors for Fecal Urgency Among Individuals With and Without Diarrhea, Based on Data From the National Health and Nutrition Examination Survey. Clinical Gastroenterology and Hepatology, 2018, 16, 1450-1458.e2.	2.4	18
40	Factors Associated With Response to Placebo in Patients With Irritable Bowel Syndrome and Constipation. Clinical Gastroenterology and Hepatology, 2018, 16, 1738-1744.e1.	2.4	33
41	Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 1569-1584.e2.	2.4	76
42	Sleep Disturbances Are Commonly Reported Among Patients Presenting to a Gastroenterology Clinic. Digestive Diseases and Sciences, 2018, 63, 2983-2991.	1.1	35
43	Psychological Interventions for Irritable Bowel Syndrome and Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology, 2017, 8, e214.	1.3	117
44	Development of the Irritable Bowel Syndrome Cognitive Affective Scale: a brief self-report measure for clinical and research settings. European Journal of Gastroenterology and Hepatology, 2017, 29, 849-854.	0.8	3
45	Psychological Considerations and Interventions in Inflammatory Bowel Disease Patient Care. Gastroenterology Clinics of North America, 2017, 46, 847-858.	1.0	36
46	Editorial: latent class analysis to improve confidence in the diagnosis of <scp>IBS</scp> . Alimentary Pharmacology and Therapeutics, 2017, 45, 1267-1268.	1.9	1
47	Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. Trials, 2017, 18, 234.	0.7	43
48	The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of <scp>IBS</scp> . Neurogastroenterology and Motility, 2017, 29, e12982.	1.6	45
49	Irritable bowel syndrome and diet. Gastroenterology Report, 2017, 5, 11-19.	0.6	37